Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

insulin pens

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Diabetes apps present usability problems for older adults

Researchers find a range of potential design problems with smartphone apps

- PMLiVE

Boehringer-Lilly tap into behavioural change for online diabetes programme

Part of the partners' Tradjenta marketing, My Well Planner offers personalised educational resources

- PMLiVE

Takeda completes new manufacturing facility in Russia

Expands Japanese firm’s presence in key emerging market

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

- PMLiVE

Lilly launches branded app for emergency diabetes medicine

US-only Lilly Glucagon iPhone and iPad app shows carers how to use the hypoglycaemia treatment

- PMLiVE

Lilly appoints Michael Harrington SVP and general counsel

Replaces Robert Armitage who retires from the pharma company

Lilly drops touted Zyprexa successor for use in schizophrenia

Pomaglumetad methionil disappoints in phase III

- PMLiVE

Lilly’s Alzheimer’s drug solanezumab stumbles, but doesn’t fall in phase III

Fails to show significant benefit, but data holds some consolation

GSK pay $3bn to settle drug-marketing case

UK drug-maker pleads guilty for promoting a number of drugs in the US off-label

- PMLiVE

Interview: Jan Lundberg, Eli Lilly

We talk to Jan Lundberg, executive VP, science and technology, and president, Lilly Research Laboratories

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links